AAC CEO visits Etta campus

Michael cartwright visits staff at oxford treatment centerTherapeutic relationship remains central to evolving approach for addiction treatment

The high-tech transformation of addiction treatment through new technologies like brain scanning will be grounded by a clinical mainstay: The essential human connection between patient and therapist.

That was the message of Michael Cartwright, CEO of American Addiction Centers, as he met recently with Oxford Treatment Center’s clinical staff. Cartwright encouraged therapists and support staff on their essential role in helping people recover from drug and alcohol addiction.

All the evidence shows that two things work best to begin a successful recovery: A long-term model of care, and the therapeutic relationship with you,” he told the team. “What you are doing is effective for the patients you serve, and I appreciate the hard work you do every day.

Earlier this summer, Cartwright released his 2030 vision for American Addiction Centers, the company he founded in 2007. AAC acquired Oxford Treatment Center in 2015.

In designing his vision for the company’s next decade, Cartwright worked with Dr. Mark Calarco, AAC’s national medical director for clinical diagnostics and the CEO of Addiction Labs. The 2030 vision for AAC centers on applying new and emerging technologies to continue reducing the “trial and error” approach and cognitive bias in addiction treatment.

“I believe imaging, bloodwork and genetics are going to revolutionize the way we do drug and alcohol treatment in the next 10 years,” Cartwright told the Oxford Treatment Center staff.

Cartwright said the company’s core mission remains unchanged: That of delivering the best possible care for people with dual-diagnosis needs, which span both substance use disorders and related mental illnesses.

In the years to come, AAC aims to grow its focus in pharmacogenetics, honing the ability to tailor medication choices to a patient’s unique DNA. The company also anticipates beginning to use brain scans for psychiatric indications and mental health. Expanding access to nutraceuticals to reduce inflammation and aid in treating depressive symptoms is also a goal, along with investments in medical technology.

Learn more about AAC’s 2030 vision: https://www.prnewswire.com/news-releases/the-science-behind-the-2030-vision-for-american-addiction-centers-and-how-it-will-revolutionize-the-treatment-of-addiction-300858788.html


This release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are made only as of the date of this release. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements may include information concerning AAC Holdings, Inc.’s (collectively with its subsidiaries; “AAC Holdings” or the “Company”) possible or assumed future results of operations, including descriptions of the Company’s revenue, profitability, outlook and overall business strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from the information contained in the forward-looking statements. These risks, uncertainties and other factors include, without limitation: (i) the Company’s inability to effectively operate its facilities; (ii) the Company’s reliance on its sales and marketing program to continuously attract and enroll clients; (iii) a reduction in reimbursement rates by certain third-party payors for inpatient and outpatient services and point-of-care and definitive lab testing; (iv) the Company’s failure to successfully achieve growth through acquisitions and de novo projects; (v) risks associated with estimates of the value of accounts receivable or deterioration in collectability of accounts receivable; (vi) a failure to achieve anticipated financial results from contemplated and prior acquisitions; (vii) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of an acquisition; (viii) the Company’s failure to achieve anticipated financial results from contemplated and prior acquisitions; (ix) a disruption in the Company’s ability to perform diagnostic laboratory services; (x) maintaining compliance with applicable regulatory authorities, licensure and permits to operate the Company’s facilities and laboratories; (xi) a disruption in the Company’s business and reputational and economic risks associated with the civil securities claims brought by shareholders or claims by various parties; (xii) inability to meet the covenants in the Company’s loan documents or lack of borrowing capacity; and (xiii) general economic conditions, as well as other risks discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 and other filings with the Securities and Exchange Commission. As a result of these factors, we cannot assure you that the forward-looking statements in this release will prove to be accurate. Investors should not place undue reliance upon forward-looking statements.